Trials / Completed
CompletedNCT02953704
Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)
Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients With Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,469 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this prospective, longitudinal, noninterventional study is to describe clinical characteristics, evolution of disease burden, and treatment patterns in patients with select subcategories of essential thrombocythemia (ET) or myelofibrosis (MF).
Conditions
Timeline
- Start date
- 2016-12-31
- Primary completion
- 2022-03-29
- Completion
- 2022-03-29
- First posted
- 2016-11-03
- Last updated
- 2022-05-13
Locations
116 sites across 2 countries: United States, Puerto Rico
Source: ClinicalTrials.gov record NCT02953704. Inclusion in this directory is not an endorsement.